Tirzepatide versus Semaglutide for Type 2 Diabetes
Not all patients with type 2 diabetes have adequate glucose control with metformin. Tirzepatide is an injectable therapy that combines a glucose-dependent insulinotropic polypeptide with a GLP-1 receptor agonist. How it compares with semaglutide — an FDA-approved selective GLP-1 receptor agonist — is unknown. New research findings are summarized in a short video.
Copyright © 2021 Massachusetts Medical Society.
